Michael Gibertini Joins Elligo as Chief Development Officer
Source:

Elligo Health Research

July 28, 2020

Elligo Health Research is proud to welcome Michael Gibertini, Ph.D., to its leadership team. Gibertini joins the team at the healthcare-enabling company as the new chief development officer and will develop new lines of business to support Elligo’s mission to bring clinical research as a care option to patients.

An industry veteran, Gibertini brings over 30 years of experience to Elligo. His unique strength molding service lines to implement teams and processes for complex studies in various therapeutic areas will provide vision, leadership, and operational direction for new Elligo products and services.

As chief development officer, Gibertini will work to expand Elligo’s System of Accelerated Research (SOAR™), a model for hybrid and decentralized trials (DCTs) with fully remote monitoring capabilities. Built from a clinical control layer (CCL), the system drives efficiency through direct data from source to submission, enabling patients, clinicians, and sponsors to conduct more efficient trials in traditional and DCT models with the solution.

Prior to joining the team, Gibertini served as the president of clinical development at Syneos Health (formerly INC Research) leading a high-growth, scientifically oriented CNS business unit. During his tenure at the company, he was responsible for multiple organizational innovations that produced industry-leading growth and success.

“We are thrilled to welcome Michael to Elligo,” said John Potthoff, Ph.D., CEO of Elligo. “The role of chief development officer is integral to developing new lines of business that help us achieve our mission. He is already making a positive impact in our efforts to prioritize research as a healthcare option for our diverse pool of patients.”

About Elligo Health Research®
Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our Goes Direct® approach and novel IntElligo® Research Stack clinical technology, our team provides access to the best healthcare experts, patients, and research technologies. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at elligodirect.com.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK